News & Updates

Isolated hepatitis B core antibody (anti-HBc) positivity appears to increase the risk of liver-related and liver cancer mortality, particularly when accompanied by a high fibrosis score, according to a study of Korean adults.

A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.

Oral supplementation with 1-kestose in patients with mild to moderate ulcerative colitis helps modulate the gut microbiome, which in turn contributes to clinical improvement, as reported in a study.

The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).

Treatment with single fraction radiation therapy (RT) results in lesser hepatic pain in most patients with end-stage hepatocellular carcinoma (HCC) or liver metastases, according to a study presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).

Increased consumption of plant-based foods is associated with a lower risk of developing colorectal cancer (CRC) in men, according to the Multiethnic Cohort study.

Tumour response-speed heterogeneity to first-line chemotherapy is predictive of early disease progression and shorter survival in patients with metastatic colorectal cancer, reveals a study.